You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it. In addition as per local health authority Regulations, some of our products are not approved for sales, marketing or distribution in all countries.
NO
YES
NEWS / CORPORATE / .........

CORPORATE - 20-03-2020

Letter to patient associations and scientific organizations

Kedrion’s production network is fully operational. We are meeting expectations in our production cycle, notably, plasma collection in Italy and abroad and quality production of each of our medicines, including Factor VIII, Factor IX and Immunoglobulins.

We are a long-standing pharmaceutical company which processes biological material (human plasma) into medicines and therapies for treating rare and debilitating diseases, a factor which enhances our capacity to react in the face of an unexpected emergency.

From the beginning of the present crisis we have adopted all necessary measures to minimize every possible risk to our activity; our response has resulted in an unbroken continuity in plasma supply, processing, production, warehousing and distribution of our medicines. This applies to all our products and all the countries in which we operate.

We are continuing to monitor the situation and will advise you of any future significant developments.

Today, more than ever, during this difficult time for our country and for the world, our commitment, our dedication and our efforts aim to guarantee continuity and quality of our services in supporting the patient communities.


Paolo Marcucci
Chairman & CEO

For more information please contact: pressoffice@kedrion.com